Meeting
2024 ASCO Gastrointestinal Cancers Symposium
HLX22 plus HLX02 and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer: A randomized, double-blind, multicenter phase 2 study.
Authors
Jin Li
Department of Medical Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China
Jin Li , Yong Gao , Ning Li , Meng Qiu , Yan-Qiao Zhang , Mudan Yang , Linzhi Lu , Wei Li , Yuntao Ma , Xiaoming Hou , Guoping Sun , Mingquan Cai , Jingran Wang , Jianwei Lu , Diansheng Zhong , Futang Yang , Jing Li , Qingyu Wang , Jun Zhu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04908813
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 354)
DOI
10.1200/JCO.2024.42.3_suppl.354
Abstract #
354
Poster Bd #
G15
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Atezolizumab and trastuzumab plus chemotherapy in patients with HER2+ locally advanced resectable gastric cancer or adenocarcinoma of the gastroesophageal junction: A multicenter, randomized, open-label phase II study.
First Author: Zhi Peng
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase I/IIa open label, nonrandomized, multicenter study of CYNK-101 in combination with trastuzumab and pembrolizumab in patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
First Author: Martin Gutierrez
Poster
2023 ASCO Gastrointestinal Cancers Symposium
TST001 (a high affinity humanized anti-claudin18.2 monoclonal antibody) in combination with nivolumab plus capecitabine and oxaliplatin as first-line or with nivolumab as late-line treatment in locally advanced and metastatic gastric/gastroesophageal junction (G/GEJ) cancer: Design of cohorts from a phase I/IIa study (TST001-1002).
First Author: Weijian Guo
Poster
2021 Gastrointestinal Cancers Symposium
Margetuximab (M) combined with anti-PD-1 (retifanlimab) or anti-PD-1/LAG-3 (tebotelimab) +/- chemotherapy (CTX) in first-line therapy of advanced/metastatic HER2+ gastroesophageal junction (GEJ) or gastric cancer (GC).
First Author: Daniel V.T. Catenacci